Montara Therapeutics is advancing precision medicine for central nervous system disorders with its BrainOnly™ platform. This innovative approach addresses neurodegenerative and neurological diseases by combining a brain-penetrant, target-specific drug with a non-brain-penetrant peripheral blocker. This strategy prevents peripheral toxicities while enhancing drug efficacy in the brain. The platform is based on research from UCSF and is licensed from them. Montara’s technology aims to tackle previously undruggable targets and improve safety and effectiveness in treating conditions like Alzheimer’s, Parkinson’s, and brain cancers.